IPP Bureau
RH Capital announces investments to improve women’s health
By IPP Bureau - June 04, 2022
RH Capital, a leading women's health venture capital fund, announced three new investments to improve health outcomes for women in the US.
LEO Pharma strengthens its commercial organization
By IPP Bureau - June 03, 2022
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
CMP Pharma announces calcium channel blocker ‘Norliqva’ availability
By IPP Bureau - June 03, 2022
Norliqva was approved by the FDA on February 24, 2022 and is now available through normal retail distribution.
Lockwood acquires medical animation studio ‘Random42’ from Graphite Capital
By IPP Bureau - June 03, 2022
The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.
Sanofi India appoints Preeti Futnani as GM, Vaccines
By IPP Bureau - June 03, 2022
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
David Kendall named Zealand Pharma CMO
By IPP Bureau - June 03, 2022
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
Gilead Sciences appoints Stacey Ma as EVP, Pharmaceutical Development and Manufacturing
By IPP Bureau - June 03, 2022
Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead
GXO Logistics opens new warehouse for pharmaceutical sector
By IPP Bureau - June 03, 2022
Facility features LED lighting, solar panels, automation and innovative temperature-controlled systems to maximize efficiency and minimize environmental impact
Mitsubishi Tanabe Pharma America presents 48-week results from phase 3 safety clinical study of Radicava ORS
By IPP Bureau - June 03, 2022
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
GSK to acquire clinical-stage biopharmaceutical company Affinivax for US$ 3.3 billion
By IPP Bureau - June 03, 2022
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
GSK to form consumer healthcare business ‘Haleon’
By IPP Bureau - June 03, 2022
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Evonik to build new lipid production facility for mRNA-based therapies in U.S.
By IPP Bureau - June 03, 2022
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
How would AI change manufacturing & packaging processes?
By IPP Bureau - June 03, 2022
These and many other questions gather worldwide experts of the pharmaceutical industry at the PHARMAP 2022 which takes place in Berlin, Germany on June, 20 - 21, 2022
Ovensa and Celanese to collaborate to advance precision drug delivery
By IPP Bureau - June 02, 2022
Vial to launch oncology CRO, Arati Rao named as First Advisor
By IPP Bureau - June 02, 2022
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
